Calendar of Events

Nov
9
Mon
2020
Family History in Cancer Screening and Treatment – Elizabeth Hopp, MD @ Virtual
Nov 9 @ 5:45 pm – 7:00 pm


Please join us virtually. This talk will detail what constitutes a significant family history along with discussion of genetic testing. The talk will also touch on management of hereditary cancer syndromes, such as Lynch syndrome and BRCA.

Presentation by: Elizabeth Hopp, MD, Gynecologic Oncologist

Register Online

Register online through the link to Froedtert’s classes and events below.

May
13
Thu
2021
Autoimmune Disorders and Fertility with Jayme Bosler, MD @ Virtual Event (register below)
May 13 @ 6:00 pm – 7:00 pm

Please join us virtually! Women with existing autoimmune diseases may be at higher risk of infertility and some autoimmune conditions can increase a woman’s risk of miscarriage.

Together we will discuss these conditions and what to do to increase your chances of a successful pregnancy.

We will also explain the impact of preeclampsia on a woman’s future heart health.

Presentation by: Jayme Bosler, MD, Reproductive Endocrinology and Infertility physician

Register Online

Register online through the link to Froedtert’s classes and events below.

May
19
Wed
2021
Patient Education Webinar: Urinary Incontinence with Dr. Emily Davidson @ Virtual Event (register below)
May 19 @ 12:00 pm – 1:00 pm

Urinary issues including urgency and leakage are not something you should have to live with or schedule your life around. Learn about types of leakage and the options that exist for treatment.

Presentation by: Emily Davidson, MD, Urogynecologist

Sep
25
Sat
2021
Ray of Hope 5K Run/ 2K Walk for Ovarian Cancer Research (in person race with virtual option) @ Hoyt Park 1800 N Swan Blvd Wauwatosa, WI US 53226
Sep 25 @ 9:00 am – 12:00 pm
Ray of Hope 5K Run/ 2K Walk for Ovarian Cancer Research (in person race with virtual option) @ Hoyt Park 1800 N Swan Blvd Wauwatosa, WI US 53226

Join us September 25th for the Ray of Hope’s 3rd Annual Race! Help us run or walk to raise funds for ovarian cancer. All proceeds go directly to our researchers working hard to identify novel targets and treatment strategies to cure ovarian cancer.

Ray of Hope is a non-profit organization established in 2018 in the Greater Milwaukee Area in response to the need for more advocacy for ovarian cancer awareness and research. Ray of hope provides philanthropic support to ovarian cancer researchers like us to generate preliminary data to apply for high-risk and high-reward federal grants. Ray of hope believes in the bravery of all women who have fought or are fighting against ovarian cancer. Ray of hope is working for women around the globe to be brave and resilient in the fight against ovarian cancer – – and their bravery should not go unnoticed.

Sunila Pradeep, PhD’s laboratory is partnering in the mission of Ray of Hope by identifying novel targets and treatment strategies to cure ovarian cancer.

Sep
27
Wed
2023
Application of Human Amniotic Membrane in Tissue Engineering – Bo Wang, PhD @ Ob-Gyn Conference Room #252 (2nd floor Wisconsin Diagnostic Lab Building)
Sep 27 @ 12:00 pm – 1:00 pm

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

Presented by

Bo Wang, PhD
Director – Tissue Regenerative Engineering Laboratory (TRE Lab)
Assistant Professor – Department of Biomedical Engineering, The Marquette University and Medical College of Wisconsin

About

Dr. Bo Wang, Director and Principal Investigator of the TRE Lab, received her PhD in Biomedical Engineering from Mississippi State University in 2012 and completed her Postdoctoral Fellowship at Northwestern University’s Feinberg School of Medicine, Department of Surgery, in 2016. She joined the Marquette-MCW Joint Department of Biomedical Engineering in January of 2019 with research interests that include stem cell engineering, hard-tissue engineering and 3D bioprinting, as well as vascular tissue engineering, imaging, modeling and simulation.

The Tissue Regenerative Engineering Laboratory is developing bio-functional engineered tissues that provide advanced therapeutic options for such conditions as birth defects, bone disorders, and liver and vascular diseases. To do this, the TRE Lab will first develop a greater understanding of the biological and molecular processes involved in regenerative regression.

Learn more about the WHRP Seminars[/vc_column_text][/vc_column][/vc_row]

Mar
27
Wed
2024
“Advances Toward the Next Generation Tools For Precision Medicine” – Navonil De Sarkar, PhD @ Ob-Gyn Conference Room #252 (2nd floor Wisconsin Diagnostic Lab Building)
Mar 27 @ 12:10 pm – 1:10 pm

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” z_index=””][vc_column][vc_column_text]

Presented by

Navonil De Sarkar, PhD
Assistant Professor – Department of Pathology at the Medical College of Wisconsin

About

Navonil De Sarkar is an Assistant Professor at the Medical College of Wisconsin Cancer Center with a dual background in computational and experimental genomics; he brings a multidisciplinary approach to studying human cancers. His research focuses on understanding the natural history of the disease, devising noninvasive approaches to track adaptive and molecular evolutionary changes in cancer accurately, and ultimately developing practical strategies for precision medicine in advanced cancer patients (Augmented precision medicine).

Navonil received his Ph.D. from the Indian Statistical Institute and joined Peter Nelson’s lab at the University of Washington & Fred Hutchinson Cancer Research Center, Seattle, for postdoctoral training. Through adopting integrative genomics approaches, Navonil developed extensive experience analyzing tumor genomes to study functionally relevant mutations and structural aberrations using tumor tissue and circulating tumor DNA (ctDNA). Navonil participated in several large-scale consortium data analyses, including Stat-up-to-cancer germline and prostate tumor analysis efforts. Navonil led the bioinformatics analysis of the large-scale germline sequence work that highlighted the importance of inherited DNA repair genes in shaping the fate of advanced prostate cancer. He is one of the early discoverers of CDK12 loss-associated tandem duplicator signature. Subsequently, De Sarkar developed a machine learning-based classifier that accurately predicts functional homologous recombination deficiency. Recently, he co-led a study interrogating whole genomes of advanced prostate cancers using cell-free DNA sequencing and discovered imprints of cancer epigenomes in native cell-free DNA sequence data.

Navonil is a recipient of several trainee awards. To mention in 2019 Navonil received the very competitive Prostate Cancer Foundation Young Investigator Award. Then onwards, Navonil is co-leading Prostate Cancer Foundation DNA repair-focused working group activities. He is the editorial board member for Translational Oncology and an associate editor for the Genitourinary Oncology edition of Frontiers journals.

Navonil re-joined MCW in March 2023 and committed to establishing a multidisciplinary research group to develop cutting-edge but practical precision medicine tools for prostate and other cancers. Building on strong biological fundamentals and detailed understandings of the disease, De Sarkar Lab (DeTAnomics Lab) is developing novel therapeutic strategies and working to co-develop new genomic assays and computational genomics tools to help us tackle the most lethal types of prostate and other cancers. DeTAnomics Lab adopts long-read genomic sequencing techniques to better understand cancer genome, transcriptome, and epigenome. In the lab, DeTAnomics lab explores the complex interplay between the genome and epigenome to uncover new insights that can lead to the development of more effective therapeutics and biomarkers. Currently, DeSarkar and his team are working on developing a practical strategy to degrade BRCA2 in tumor cells so as to confer DNA-damaging mediated therapy benefits to a wider pool of patients.

Learn more about the WHRP Seminars[/vc_column_text][/vc_column][/vc_row]